HROW
Price
$38.82
Change
-$1.19 (-2.97%)
Updated
Aug 15 closing price
Capitalization
1.48B
93 days until earnings call
OGI
Price
$1.43
Change
-$0.13 (-8.33%)
Updated
Aug 15 closing price
Capitalization
208.05M
Interact to see
Advertisement

HROW vs OGI

Header iconHROW vs OGI Comparison
Open Charts HROW vs OGIBanner chart's image
Harrow
Price$38.82
Change-$1.19 (-2.97%)
Volume$881.45K
Capitalization1.48B
Organigram Global
Price$1.43
Change-$0.13 (-8.33%)
Volume$1.07M
Capitalization208.05M
HROW vs OGI Comparison Chart in %
Loading...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HROW vs. OGI commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a Hold and OGI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (HROW: $40.01 vs. OGI: $1.56)
Brand notoriety: HROW and OGI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HROW: 226% vs. OGI: 282%
Market capitalization -- HROW: $1.48B vs. OGI: $208.05M
HROW [@Pharmaceuticals: Generic] is valued at $1.48B. OGI’s [@Pharmaceuticals: Generic] market capitalization is $208.05M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.83B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HROW’s FA Score shows that 1 FA rating(s) are green whileOGI’s FA Score has 1 green FA rating(s).

  • HROW’s FA Score: 1 green, 4 red.
  • OGI’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than OGI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 6 TA indicator(s) are bullish while OGI’s TA Score has 7 bullish TA indicator(s).

  • HROW’s TA Score: 6 bullish, 4 bearish.
  • OGI’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, OGI is a better buy in the short-term than HROW.

Price Growth

HROW (@Pharmaceuticals: Generic) experienced а +20.48% price change this week, while OGI (@Pharmaceuticals: Generic) price change was +10.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($1.48B) has a higher market cap than OGI($208M). HROW YTD gains are higher at: 19.255 vs. OGI (-3.106). HROW has higher annual earnings (EBITDA): 18.6M vs. OGI (-5.23M). HROW has more cash in the bank: 66.7M vs. OGI (14.1M). OGI has less debt than HROW: OGI (9.54M) vs HROW (230M). HROW has higher revenues than OGI: HROW (213M) vs OGI (194M).
HROWOGIHROW / OGI
Capitalization1.48B208M712%
EBITDA18.6M-5.23M-356%
Gain YTD19.255-3.106-620%
P/E RatioN/A12.28-
Revenue213M194M110%
Total Cash66.7M14.1M473%
Total Debt230M9.54M2,412%
FUNDAMENTALS RATINGS
HROW vs OGI: Fundamental Ratings
HROW
OGI
OUTLOOK RATING
1..100
1915
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
45100
SMR RATING
1..100
9784
PRICE GROWTH RATING
1..100
4445
P/E GROWTH RATING
1..100
1127
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OGI's Valuation (55) in the null industry is in the same range as HROW (85) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for OGI (100) in the null industry. This means that HROW’s stock grew somewhat faster than OGI’s over the last 12 months.

OGI's SMR Rating (84) in the null industry is in the same range as HROW (97) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to HROW’s over the last 12 months.

HROW's Price Growth Rating (44) in the Pharmaceuticals Other industry is in the same range as OGI (45) in the null industry. This means that HROW’s stock grew similarly to OGI’s over the last 12 months.

HROW's P/E Growth Rating (11) in the Pharmaceuticals Other industry is in the same range as OGI (27) in the null industry. This means that HROW’s stock grew similarly to OGI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROWOGI
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
81%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BELGF0.610.03
+4.78%
Bellevue Gold, Ltd.
NVZMF67.38N/A
N/A
NOVONESIS A S
AKAAF69.00N/A
N/A
Aker AS
BVAXF0.02N/A
-1.38%
BioVaxys Technology Corp.
GBUX0.70-0.08
-10.45%
GIVBUX INC.

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+9.62%
AMRX - HROW
46%
Loosely correlated
-0.11%
EBS - HROW
39%
Loosely correlated
+0.34%
OGI - HROW
34%
Loosely correlated
-2.50%
VTRS - HROW
32%
Poorly correlated
+2.69%
ELAN - HROW
30%
Poorly correlated
+1.07%
More

OGI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGI has been loosely correlated with ACB. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if OGI jumps, then ACB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGI
1D Price
Change %
OGI100%
-2.50%
ACB - OGI
60%
Loosely correlated
-2.53%
CGC - OGI
59%
Loosely correlated
-9.15%
CRON - OGI
59%
Loosely correlated
-3.82%
TLRY - OGI
56%
Loosely correlated
-5.60%
ELAN - OGI
32%
Poorly correlated
+1.07%
More